Clinical Improvement After Treatment With IncobotulinumtoxinA (XEOMIN®) in Patients With Cervical Dystonia Resistant to Botulinum Toxin Preparations Containing Complexing Proteins

Clinical Improvement After Treatment With IncobotulinumtoxinA (XEOMIN®) in Patients With Cervical Dystonia Resistant to Botulinum Toxin Preparations Containing Complexing Proteins

This study investigated the clinical long-term effect of incobotulinumtoxinA (incoBoNT/A) in 33 cervical dystonia (CD) patients who had developed partial secondary therapy failure (PSTF) under previous long-term botulinum toxin (BoNT) treatment. Patients were treated four times every 12 weeks with i...

Full description

Bibliographic Details
Main Authors:	Harald Hefter, Christian J. Hartmann, Ulrike Kahlen, Sara Samadzadeh, Dietmar Rosenthal, Marek Moll
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-02-01
Series:	Frontiers in Neurology
Subjects:	incobotulinumtoxinA cervical dystonia complexing proteins partial secondary therapy failure neutralizing antibodies
Online Access:	https://www.frontiersin.org/articles/10.3389/fneur.2021.636590/full

Similar Items

Pain Reduction in Cervical Dystonia Following Treatment with IncobotulinumtoxinA: A Pooled Analysis
by: Alberto Albanese, et al.
Published: (2023-05-01)

Pooled Safety Analysis of IncobotulinumtoxinA in the Treatment of Neurological Disorders in Adults
by: Wolfgang H. Jost, et al.
Published: (2023-05-01)

Efficacy and safety of two incobotulinumtoxinA injection intervals in cervical dystonia patients with inadequate benefit from standard injection intervals of botulinum toxin: Phase 4, open-label, randomized, noninferiority study
by: Cynthia Comella, et al.
Published: (2022-01-01)

Botulinum toxin A (IncobotulinumtoxinA) and pneumoperitoneum image-guided for hernia repair with loss of dominance
by: Sergio E. López-Juárez, et al.
Published: (2023-01-01)

Effects of Ultrasound-Guided Administration of Botulinum Toxin (IncobotulinumtoxinA) in Patients with Lateral Epicondylitis
by: Antonio Galván Ruiz, et al.
Published: (2019-01-01)

Outcomes of IncobotulinumtoxinA Injection on Myalgia and Arthralgia in Patients Undergoing Temporomandibular Joint Arthroscopy: A Randomized Controlled Trial
by: David Faustino Ângelo, et al.
Published: (2023-06-01)

Cost-Effectiveness of IncobotulinumtoxinA in the Treatment of Sialorrhea in Patients with Various Neurological Conditions
by: Koji Makino, et al.
Published: (2020-03-01)

Efficacy and Safety of IncobotulinumtoxinA in the Treatment of Lower Limb Spasticity in Japanese Subjects
by: Yoshihisa Masakado, et al.
Published: (2022-03-01)

Quality of life in subjects with upper- and lower-limb spasticity treated with incobotulinumtoxinA
by: Klemens Fheodoroff, et al.
Published: (2020-03-01)

Pain Reduction in Adults with Limb Spasticity Following Treatment with IncobotulinumtoxinA: A Pooled Analysis
by: Jörg Wissel, et al.
Published: (2021-12-01)

Safety Profile and Lack of Immunogenicity of IncobotulinumtoxinA in Pediatric Spasticity and Sialorrhea: A Pooled Analysis
by: Steffen Berweck, et al.
Published: (2022-08-01)

Tolerability and Efficacy of Customized IncobotulinumtoxinA Injections for Essential Tremor: A Randomized, Double-Blind, Placebo-Controlled Study
by: Mandar Jog, et al.
Published: (2020-12-01)

Improvement in Quality-of-Life-Related Outcomes Following Treatment with IncobotulinumtoxinA in Adults with Limb Spasticity: A Pooled Analysis
by: Franco Molteni, et al.
Published: (2023-12-01)

Tailored botulinum toxin type A injections in aesthetic medicine: consensus panel recommendations for treating the forehead based on individual facial anatomy and muscle tone
by: Anido J, et al.
Published: (2017-10-01)

Factors Influencing the Surgical Decision in Dystonia Patients Referred for Deep Brain Stimulation
by: Carolina Gorodetsky, et al.
Published: (2021-07-01)

Considerations on patient-related outcomes with the use of botulinum toxins: is switching products safe?
by: Fraint A, et al.
Published: (2016-02-01)

Spotlight on botulinum toxin and its potential in the treatment of stroke-related spasticity
by: Kaku M, et al.
Published: (2016-03-01)

One21: A Novel, Customizable Injection Protocol for Treatment of the Forehead with IncobotulinumtoxinA
by: de Sanctis Pecora C
Published: (2020-02-01)

Botulinum toxin therapy (Incobotulinumtoxin А) in the complex rehabilitation of adolescents with cerebral palsy (clinical case)
by: E. V. Kostenko, et al.
Published: (2018-05-01)

Safety and Effectiveness of Repeated Botulinum Toxin A Intracavernosal Injections in Men with Erectile Dysfunction Unresponsive to Approved Pharmacological Treatments: Real-World Observational Data
by: François Giuliano, et al.
Published: (2023-06-01)

IncobotulinumtoxinA in the treatment of sialorrhea in patients with infantile cerebral palsy
by: A. L. Kurenkov, et al.
Published: (2021-08-01)

“Pseudo”-Secondary Treatment Failure Explained via Disease Progression and Effective Botulinum Toxin Therapy: A Pilot Simulation Study
by: Harald Hefter, et al.
Published: (2023-10-01)

Profile of Xeomin&reg; (incobotulinumtoxinA) for the treatment of blepharospasm
by: Park J, et al.
Published: (2011-06-01)

The Impact of the Course of Disease before Botulinum Toxin Therapy on the Course of Treatment and Long-Term Outcome in Cervical Dystonia
by: Harald Hefter, et al.
Published: (2021-07-01)

Post hoc analysis of the improvement in shoulder spasticity and safety observed following treatment with incobotulinumtoxinA
by: Jörg Wissel, et al.

Botulinum neurotoxin type A in the interdisciplinary treatment of sialorrhea in adults and children—update and practice recommendations
by: Wolfgang H. Jost, et al.
Published: (2023-12-01)

Russian consensus on the use of incobotulinumtoxinA in children with cerebral palsy for the treatment of spasticity and sialorrhea
by: A. L. Kurenkov, et al.
Published: (2022-04-01)

IncobotulinumtoxinA for the Treatment of Glabella and Forehead Dynamic Lines: A Real-Life Longitudinal Case Series
by: da Cunha ALG, et al.
Published: (2023-03-01)

The Extreme Ends of the Treatment Response Spectrum to Botulinum Toxin in Cervical Dystonia
by: Sara Samadzadeh, et al.
Published: (2020-12-01)

Disease Progression of Idiopathic Cervical Dystonia in Spite of Improvement After Botulinum Toxin Therapy
by: Harald Hefter, et al.
Published: (2020-11-01)

The Use of High Initial Doses of Botulinum Toxin Therapy for Cervical Dystonia Is a Risk Factor for Neutralizing Antibody Formation—A Monocentric Cross-Sectional Pilot Study
by: Harald Hefter, et al.
Published: (2022-01-01)

Characterization of SNARE Cleavage Products Generated by Formulated Botulinum Neurotoxin Type-A Drug Products
by: Jack Xie, et al.
Published: (2010-08-01)

The Impact of SARS-CoV-2 Pandemic Lockdown on a Botulinum Toxin Outpatient Clinic in Germany
by: Sara Samadzadeh, et al.
Published: (2021-01-01)

Efficacy and Safety of IncobotulinumtoxinA in Subjects Previously Treated with Botulinum Toxin versus Toxin-Naïve Subjects with Cervical Dystonia
by: Hubert Fernandez, et al.
Published: (2013-05-01)

Real-World Dosing of OnabotulinumtoxinA and IncobotulinumtoxinA for Cervical Dystonia and Blepharospasm: Results from TRUDOSE and TRUDOSE II
by: Ruth Kent, et al.
Published: (2021-07-01)

Lessons about Botulinum Toxin A Therapy from Cervical Dystonia Patients Drawing the Course of Disease: A Pilot Study
by: Harald Hefter, et al.
Published: (2023-06-01)

Trigeminal neuralgia: IncobotulinumtoxinA (Xeomin), can it decrease the pharmacological intervention? (A case series)
by: Meghdad Hosseini, et al.
Published: (2023-03-01)

The burden of sialorrhoea in chronic neurological conditions: current treatment options and the role of incobotulinumtoxinA (Xeomin®)
by: Francesca Morgante, et al.
Published: (2019-11-01)

Use of botulinum toxin in the management of dystonia in Parkinson’s disease
by: Charenya Anandan, et al.
Published: (2024-04-01)

FDA Approvals and Consensus Guidelines for Botulinum Toxins in the Treatment of Dystonia
by: Lauren L. Spiegel, et al.
Published: (2020-05-01)